BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 31072670)

  • 1. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
    Lopez-Aguiar AG; Zaidi MY; Beal EW; Dillhoff M; Cannon JGD; Poultsides GA; Kanji ZS; Rocha FG; Marincola Smith P; Idrees K; Beems M; Cho CS; Fisher AV; Weber SM; Krasnick BA; Fields RC; Cardona K; Maithel SK
    Ann Surg Oncol; 2019 Aug; 26(8):2517-2524. PubMed ID: 31004295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).
    Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG
    Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
    Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
    Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
    Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
    J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional Metastatic Behavior of Nonfunctional Pancreatic Neuroendocrine Tumors: Impact of Lymph Node Positivity on Survival.
    Jutric Z; Grendar J; Hoen HM; Cho SW; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
    Pancreas; 2017 Aug; 46(7):898-903. PubMed ID: 28697130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.
    Zaidi MY; Lopez-Aguiar AG; Dillhoff M; Beal E; Poultsides G; Makris E; Rocha F; Crown A; Idrees K; Marincola Smith P; Nathan H; Beems M; Abbott D; Barrett JR; Fields RC; Davidson J; Cardona K; Maithel SK
    JAMA Surg; 2019 Feb; 154(2):134-140. PubMed ID: 30383112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
    Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
    J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single center experience and systematic review of the literature.
    Iwasaki T; Nara S; Kishi Y; Esaki M; Shimada K; Hiraoka N
    Langenbecks Arch Surg; 2017 Sep; 402(6):925-933. PubMed ID: 27915372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sporadic nonfunctional pancreatic neuroendocrine tumors: Risk of lymph node metastases and aggressiveness according to tumor size: A multicenter international study.
    Perinel J; Nappo G; Zerbi A; Heidsma CM; Nieveen van Dijkum EJM; Han HS; Yoon YS; Satoi S; Demir IE; Friess H; Vashist Y; Izbicki J; Muller AC; Gloor B; Sandini M; Gianotti L; Subtil F; Adham M
    Surgery; 2022 Sep; 172(3):975-981. PubMed ID: 35623953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors.
    Zhang Z; Liu M; Ji S; Luo G; Xu W; Liu W; Hu Q; Sun Q; Ye Z; Qin Y; Fan G; Yu X; Xu X
    Pancreas; 2020 Mar; 49(3):381-386. PubMed ID: 32132507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?
    Chivukula SV; Tierney JF; Hertl M; Poirier J; Keutgen XM
    Surgery; 2020 Jan; 167(1):180-186. PubMed ID: 31537303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors.
    Gaitanidis A; Patel D; Nilubol N; Tirosh A; Kebebew E
    J Clin Endocrinol Metab; 2018 Jan; 103(1):187-195. PubMed ID: 29069375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR; Wang SC; Bergsland EK; Venook AP; Warren RS; Kim GE; Nakakura EK
    Pancreas; 2012 Aug; 41(6):840-4. PubMed ID: 22781907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
    Sallinen V; Haglund C; Seppänen H
    Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.
    Sahara K; Tsilimigras DI; Mehta R; Moro A; Paredes AZ; Lopez-Aguiar AG; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Poultsides GA; Makris E; Cho C; Beems M; Dillhoff M; Maithel SK; Endo I; Pawlik TM
    Ann Surg Oncol; 2020 Apr; 27(4):1203-1212. PubMed ID: 31838609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.